Clinical Trial Update: Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, immunogenicity, and ex vivo efficacy of the Pfs25-IMX313/Matrix-M malaria vaccine in healthy volunteers in Bagamoyo, Tanzania. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• Pfs25-IMX313/Matrix-M vaccine

Snippet

Sponsor: University of Oxford | Conditions: Malaria,Falciparum | Phase 1 | Status: TERMINATED